<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-114 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-114</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-114</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <p><strong>Paper ID:</strong> paper-164502a687f04effb4ac5dadbdd9d806fde4264c</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/164502a687f04effb4ac5dadbdd9d806fde4264c" target="_blank">Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Clinical Oncology</p>
                <p><strong>Paper TL;DR:</strong> This study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers and indicates that prospective mutation testing in these patients should successfully assign a targeted therapy in the majority of cases.</p>
                <p><strong>Cost:</strong> 0.019</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e114.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e114.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KIF5B-ALK</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KIF5B-ALK fusion oncokinase</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An alternative ALK fusion partner reported in lung cancer; proposed here as a candidate explanation for tumors that lack canonical EGFR/HER2/KRAS/BRAF/EML4-ALK alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>targeted mutational screening (PCR/sequencing) with complementary exon-array and SNP-array analysis for rearrangements/copy-number</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>52 surgically resected lung adenocarcinomas from East Asian never-smokers; 5 of 52 (9.6%) were 'driver-negative' for tested RTK/RAS/RAF alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Tumors lacking mutations in EGFR, HER2, KRAS, BRAF and lacking EML4-ALK fusions as assayed by RT-PCR/sequencing; also negative for NRAS, HRAS and LKB1 mutations by sequencing.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>KIF5B-ALK (non-EML4 ALK fusion)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>gene fusion (oncogenic kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Authors cite prior reports of non-EML4 ALK fusions (KIF5B-ALK) as a plausible alternative driver in the small subset of tumors with no detectable EGFR/HER2/KRAS/BRAF/EML4-ALK alterations; this is a hypothesis based on literature (ref. 33) rather than new positive detection in the study cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Within the five driver-negative tumors, exon-array analysis did not show 5' vs 3' ALK expression disparity suggestive of ALK fusions, and targeted PCR/sequencing did not detect ALK rearrangements — i.e., no supportive evidence in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Driver-negative tumors may harbor ALK rearrangements that do not involve EML4 (for example, KIF5B-ALK), which would require broader fusion detection methods or deep sequencing to identify.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e114.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e114.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS fusion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 (ROS) fusion oncogenes</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ROS1 gene fusions are oncogenic receptor tyrosine kinase rearrangements reported in lung cancer and posited here as candidate drivers for tumors lacking canonical RTK/RAS/RAF pathway alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>targeted mutational screening with preliminary exon-array and SNP-array interrogation for rearrangements/copy-number</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>52 resected lung adenocarcinomas from East Asian never-smokers; 5/52 (9.6%) without detectable EGFR/HER2/KRAS/BRAF/EML4-ALK alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Absence of EGFR, HER2, KRAS, BRAF mutations and no EML4-ALK fusions detected by PCR/sequencing; also negative for HRAS/NRAS/LKB1 mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>ROS1 fusion genes</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>gene fusion (oncogenic RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Authors list ROS fusions as possible alternative drivers to explain the small subset of pan-wild-type tumors, citing literature precedent (general suggestion only).</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Preliminary exon-array and SNP-array analyses performed by the authors did not find evidence supporting ROS fusion events in the five driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Cryptic ROS1 fusions could account for some driver-negative cases but were not detected here; unbiased deep sequencing or fusion-specific assays would be needed to confirm or refute this.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e114.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e114.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PDGFRα amplification</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Platelet-derived growth factor receptor alpha (PDGFRA) gene amplification</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Focal amplification of PDGFRA has been described as an RTK-driven mechanism in some cancers and was suggested as a candidate event in driver-negative lung adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>targeted sequencing plus preliminary exon-array and SNP-array for copy-number changes</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>52 East Asian never-smoker lung adenocarcinomas; 5/52 (9.6%) lacked known oncogenic mutations in EGFR/HER2/KRAS/BRAF/EML4-ALK.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Negative for EGFR, HER2, KRAS, BRAF mutations and EML4-ALK fusions; also tested negative for HRAS/NRAS/LKB1 mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>PDGFRA (PDGFRα) focal amplification</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>gene amplification (RTK activation)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>PDGFRα amplification is raised as a plausible candidate mechanism for oncogenic activation in driver-negative tumors based on general knowledge; authors searched their datasets for such events.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Preliminary exon-array and SNP-array analyses in this study did not find evidence of PDGFRA amplification in the five pan-wild-type tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Focal RTK amplifications (e.g., PDGFRA) could underlie a minority of tumors that are negative for canonical kinase mutations, but were not observed with the authors' preliminary genomic assays.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e114.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e114.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Other fusion/rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Unspecified novel gene fusions or genomic rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Authors hypothesize that the small proportion of tumors lacking known drivers may be driven by presently uncharacterized fusion oncogenes or other genomic rearrangements detectable only by unbiased approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>targeted mutation screens complemented by exon-array and SNP-array; authors recommend comprehensive genomic analysis/deep sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>52 resected lung adenocarcinomas from East Asian never-smokers; 5/52 (9.6%) pan-wild-type after targeted testing.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Defined as absence of mutations in tested oncogenes (EGFR, HER2, KRAS, BRAF) and absence of tested ALK fusions (EML4-ALK), plus negative for HRAS/NRAS/LKB1.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Novel/cryptic gene fusions or structural rearrangements (unspecified)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>gene fusion / structural genomic rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Rationale: targeted assays failed to identify canonical drivers in ~10% of tumors; authors note that noncanonical fusions or rearrangements (beyond those assayed) could explain these cases and that deep sequencing is required.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Preliminary exon-array and SNP-array did not reveal clear fusion or copy-number signals in these cases; no positive detections presented in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Driver-negative tumors are likely driven by cryptic structural events (novel fusion kinases or rearrangements) or other alterations not captured by the targeted panels used; unbiased whole-genome/transcriptome sequencing recommended.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e114.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e114.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PIK3CA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Activating PIK3CA mutations were detected in 4 of 52 tumors, but all co-occurred with EGFR mutations; PIK3CA is discussed as a modulator of sensitivity/resistance to EGFR-targeted therapy rather than as an independent driver in the pan-wild-type cases.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>targeted sequencing of PIK3CA exons 9 and 20</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>52 resected lung adenocarcinomas from East Asian never-smokers; PIK3CA mutations found in 4/52 (7.7%); none solely in driver-negative group (all co-occurred with EGFR mutations).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Driver-negative defined as absence of EGFR/HER2/KRAS/BRAF mutations and EML4-ALK fusions; PIK3CA mutations were not observed in those driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>PIK3CA activating mutations (but not proposed here as primary drivers of pan-wild-type tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>genetic mutation (activating point mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Sequencing found four PIK3CA mutations (exon 9 and exon 20) and all coexisted with EGFR mutations; the authors note literature associating PIK3CA alterations with resistance to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Co-occurrence with EGFR in this cohort argues PIK3CA is not the primary driver in tumors that lack EGFR/HER2/KRAS/BRAF/ALK alterations; no isolated PIK3CA-driven cases reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>PIK3CA mutations may confer TKI resistance in EGFR-mutant tumors or act as co-drivers, but do not explain the small subset of pan-wild-type tumors in this dataset.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e114.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e114.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TP53</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tumor protein p53 (TP53) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Loss-of-function TP53 mutations were detected in 15 of 52 tumors; these are common tumor-suppressor alterations but are not presented as alternative oncogenic drivers explaining RTK/RAS/RAF-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>targeted sequencing (all exons of TP53)</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>52 East Asian never-smoker lung adenocarcinomas; TP53 mutated in 15/52 (28.8%).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Driver-negative defined as lack of EGFR/HER2/KRAS/BRAF mutations and no EML4-ALK fusions; TP53 mutations were observed across the cohort but not specifically linked to driver-negative status.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>TP53 mutation (not proposed as a primary oncogenic driver replacing RTK/RAS/RAF alterations)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>genetic mutation (tumor suppressor loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Sequencing identified TP53 mutations in 15 tumors, consistent with prior studies; recognized as frequent but not necessarily oncogenic drivers in place of RTK/RAS/RAF alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Authors do not provide data that TP53 mutations alone account for the oncogenic addiction in the pan-wild-type tumors; TP53 loss is usually cooperative rather than a sole activating driver of proliferation signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>TP53 loss may cooperate with other (unidentified) genomic events in some tumors, but is unlikely to be the sole driver explaining RTK/RAS/RAF-negative adenocarcinomas in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e114.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e114.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>LKB1 (STK11)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Liver kinase B1 / serine-threonine kinase 11 (LKB1/STK11)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The LKB1 tumor suppressor was sequenced in the cohort and no mutations were detected; authors note LKB1 mutations are less frequent in Asian patients, arguing against LKB1 loss as explanation for driver-negative tumors here.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>targeted sequencing (all exons of LKB1/STK11)</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>52 resected lung adenocarcinomas from East Asian never-smokers; no LKB1 mutations detected.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Driver-negative defined as absence of canonical driver mutations (EGFR/HER2/KRAS/BRAF) and no EML4-ALK fusions; LKB1 was also assayed and found wild-type in the cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>LKB1 loss (NOT supported here)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>genetic mutation (tumor suppressor loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Sequencing found no LKB1 mutations in these samples; literature cited notes LKB1 mutations are more frequent in Caucasian than Asian lung cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Absence of LKB1 alterations in the cohort argues against LKB1 inactivation as the mechanism underlying the small set of driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>LKB1 inactivation is unlikely to explain driver-negative adenocarcinomas in this East Asian never-smoker cohort; other events should be sought.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. <em>(Rating: 2)</em></li>
                <li>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. <em>(Rating: 2)</em></li>
                <li>Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. <em>(Rating: 2)</em></li>
                <li>Somatic mutations affect key pathways in lung adenocarcinoma. <em>(Rating: 2)</em></li>
                <li>PIK3CA mutations and copy number gains in human lung cancers. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>